ACTG A5163: ALENDRONATE IN HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY

ACTG A5163：阿仑膦酸钠治疗骨矿物质密度降低的 HIV 患者

• 批准号: 7378290
• 负责人: JUDITH Ann ABERG
• 金额: $ 0.33万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378290
• 关键词: ACTG; A5163; ALENDRONATE; HIV; SUBJECTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. With the chronicity of HIV-related disease having been achieved, osteopenia has become a problem in a variable percentage of afflicted individuals. This is a phase II, randomized, placebo-controlled trial to assess the safety and efficacy of once-weekly bisphosphonate administration on osteopenia in men receiving highly active antiretroviral therapy. It will document the efficacy and safety of an intervention with Alendronate plus calcium in a double-blind fashion in reversing/arresting the degree of osteopenia at 48 weeks. Subjects continue to be enrolled on this study. No results are available yet.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。随着艾滋病毒相关疾病的慢性化已经实现，骨量减少在不同比例的患者中已经成为一个问题。这是一项II期随机安慰剂对照试验，旨在评估每周一次的双磷酸盐对接受高效抗逆转录病毒治疗的男性骨量减少症的安全性和有效性。它将证明在48周时使用阿伦磷酸钠加钙的干预在逆转/阻止骨量减少程度方面的有效性和安全性。受试者继续参加这项研究。目前还没有结果。